FOLH1 and posterior cortical atrophy: Currently, the PSMA PET imaging utilizing [68Ga]Ga-PSMA-11 or [18F]F-DCFPyL is approved by the US Food and Drug Administration (FDA) and recommended in the Guidelines of the European Association of Urology as an imaging technique of choice for the majority of patients with biochemically recurrent PCa after curative treatment and for assessment of metastases [15,16].